Diabetic maculopathy remains the major cause of loss of vision in diabetes. There is evidence to show that control of lipid levels reduces the amount of exudate in diabetic maculopathy, but to date there is no information on the effect of lipid reduction on diabetic macular oedema.
Purpose
The purpose of this case series was to compare retinal thickness using optical coherence tomography (OCT) of patients with exudative diabetic maculopathy whose only change in management was starting statins or increasing the current dose.
MethodsV"
Four patients with exudative diabetic maculopathy had serial OCT measurements to assess retinal thickness M before and after commencing or increasing their statin dose. Results
Analysis showed a reduction of macula thickness in all cases. Visual acuity also improved during the time course of the measurements.
Conclusion
Statins may aid management of diabetic maculopathy by reducing macular oedema. This case series gives the first quantified evidence of the effect of statins on reduction of diabetic macular oedema.
Yu DY, Cringle SJ, Su EN et al. Pathogenesis and intervention strategies in diabetic retinopathy . Clin Experimental Ophthalmol2001; 29:164-6.
2.
Zander E., Herfurth S., Bohl B. et al. Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Br J Ophthalmol2000;84:871-6.
3.
Su DH, Yeo KTDiabetic retinopathy and serum lipids. Singapore Med J2000;41:295-7.
4.
Cuswick M., Chew EY, Chan CC et al. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology2003;110:2126-33.
5.
Gupta A., Gupta V., Tharphar S., Bansali A.Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol2004;137:675-82.
6.
Baghdasarian SB, Jneid H., Hoogwerf BJAssociation of dyslipidemia and effects of statins on nonmacrovascular diseases. Clin Ther2004;26:337-51.
7.
Sheth HG, Aslam S., Davies N.Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits. BMJ2006;332:1272-3.
8.
Chew EY, Klein ML, Ferris FL 3rd et al. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (EDTRS) Report 22. Arch Ophthalmol1996;144:1079-84
9.
Stratton IM, Cull CA, Adler IA et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia2006; 49:1761-9.
10.
Mohan R., Mahan V., Susheela L. et al. Increased LDL cholesterol in non-insulin-dependent diabetics with maculopathy. Acta Diabetol Lat1984;21:85-9.
11.
Klein R., Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol1989;107:244-9.
12.
The Field study investigators.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus: randomised controlled trial. Lancet2005;366:1849-61.
13.
Freyberger H., Schifferdecker E., Schatz H.Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipaemic agent. Med Klin (Munich)1994;89:594-7.
14.
Goebel W., Franke R.Retinal thickness in diabetic retinopathy: comparison of optical coherence tomography, the retinal thickness analyser and fundus photography. Retina2006;26:49-57.
15.
Sandu SS, Birch MKGriffiths PG et al. Short-term effects of focal argon laser treatment in diabetic maculopathy as demonstrated by optical coherence tomography. Retina2007;27:13-20
